This year's stock market rally has left some potential winners behind, and that represents great opportunity for you to buy them for a bargain. Of course, it's not always easy to get excited about stocks that have declined. But it's important to set aside the recent stock performance and instead focus on the company's long-term earnings prospects. If the future looks bright, you may have found a player that could seriously boost your portfolio down the road.

Today, (NASDAQ: MRNA) and Doximity (NYSE: DOCS) both fit the bill. Moderna is known for its coronavirus vaccine, but it may not be a one-product company for long. The biotech aims to launch as many as 15 products in just a few years. Doximity is a platform that helps doctors connect and save time -- and the company has grown by leaps and bounds. Both Moderna and Doximity, down double digits this year, are screaming buys right now. Let's check them out.

Investors once saw Moderna's coronavirus vaccine as a reason to buy the stock, but in recent times, they've seen it as a reason to sell. That's because they've worried about the company's dependence on just one product -- especially a product linked to a pandemic situation.

Continue reading

Source Fool.com